Citations

Clear

3138 citation(s) found for "Smith, AM".

The Impact of Planned Care and a Diabetes Electronic Management System on Community-Based Diabetes Care
Montori, Víctor M. , Dinneen, Seán F. , Gorman, Colum A., Zimmerman, Bruce R., Rizza, Robert A., Bjornsen, Susan S., Bryant, Sandra C. , Smith, Steven A., Group, for The Translation Project Investigator, Green, Erin M. , Group, for The Translation Project Investigator, Montori, Victor M , Dinneen, Sean F

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 11 | Pages: 1952-1957

10.2337/diacare.25.11.1952 | PMID 12401738 Get It

OBJECTIVE—The Mayo Health System Diabetes Translation Project sought to assess models of community-based diabetes care and use of a diabetes electronic management system (DEMS). Planned care is a redesigned model of chronic disease care that involves guideline implementation, support of self-management, and use of clinical information systems. RESEARCH DESIGN AND METHODS—We studied adult diabetic patients attending three primary care practice sites in Wisconsin and Minnesota. We implemented planned care at all sites and DEMS in the practice of 16 primary care providers. We assessed quality of diabetes care using standard indicators for 200 patients randomly selected from each site at baseline and at 24 months of implementation. We used multivariable analyses to estimate the association between planned care and DEMS and each quality indicator. RESULTS—Planned care was associated with improvements in measurement of HbA1c (odds ratio 7.0 [95% CI 4.2–11.6]), HDL cholesterol (5.6 [4.1–7.5]), and microalbuminuria (5.3 [3.5–8.0]), as well as the provision of tobacco advice (6.9 [4.7–10.1]), among other performance measures. DEMS use was associated with improvements in all indicators, including microalbuminuria (3.2 [1.9–5.2]), retinal examination (2.4 [1.5–3.9]), foot examinations (2.3 [1.2–4.4]), and self-management support (2.6 [1.7–3.8]). Although planned care was associated with improvements in metabolic control, we observed no additional metabolic benefit when providers used DEMS. CONCLUSIONS—Planned care was associated with improved performance and metabolic outcomes in primary care. DEMS use augmented the impact of planned care on performance outcomes but not on metabolic outcomes. Optimal identification of the best translation of evidence to diabetes practice will require longer follow-up or new care-delivery models.
Temporal Trends in BMI Among Adults With Diabetes
Leibson, Cynthia L., Williamson, David F., Melton, L. Joseph, Smith, Steven A., Ransom, Jeanine E. , Schilling, Peter L. , Narayan, K.M. Venkat , Palumbo, Pasquale J

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 24 | Issue: 9 | Pages: 1584-1589

10.2337/diacare.24.9.1584 | PMID 11522703 Get It

OBJECTIVE—Increasing obesity within the general population has been accompanied by rising rates of diabetes. The extent to which obesity has increased among people with diabetes is unknown, as are the potential consequences for diabetes outcomes. RESEARCH DESIGN AND METHODS—Community medical records (hospital and ambulatory) of all Rochester, Minnesota, residents aged ≥30 years who first met standardized research criteria for diabetes from 1970 to 1989 (n = 1,306) were reviewed to obtain data on BMI and related characteristics as of the diabetes identification date (±3 months). Vital status as of 31 December 1999 and date of death for those who died were obtained from medical records, State of Minnesota death tapes, and active follow-up. RESULTS—As of the identification date, data on BMI were available for 1,290 cases. Of the 272 who first met diabetes criteria in 1970–1974, 33% were obese (BMI ≥30), including 5% who were extremely obese (BMI ≥40). These proportions increased to 49% (P < 0.001) and 9% (P = 0.012), respectively, for the 426 residents who first met diabetes criteria in 1985–1989. BMI increased significantly with increasing calendar year of diabetes identification in multivariable regression analysis. Analysis of survival revealed an increased hazard of mortality for BMI ≥41, relative to BMI of 23–25 (hazard ratio 1.60, 95% CI 1.09–2.34, P = 0.016). CONCLUSIONS—The prevalence of obesity and extreme obesity among individuals at the time they first met criteria for diabetes has increased over time. This is disturbing in light of the finding that diabetic individuals who are extremely obese are at increased risk of mortality compared with their nonobese diabetic counterparts.
Use of influenza and pneumococcal vaccines in people with diabetes.
Smith, Steven A., Poland, Gregory A.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 23 | Issue: 1 | Pages: 95-108

10.2337/diacare.23.1.95 | PMID 10857977 Get It

Impact of a Diabetes Electronic Management System on the Care of Patients Seen in a Subspecialty Diabetes Clinic
Smith, Steven A., Murphy, Mary E., Huschka, Todd R., Dinneen, Seán F. , Gorman, Colum A., Zimmerman, Bruce R., Rizza, Robert A., Naessens, James M. , Dinneen, Sean F

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 21 | Issue: 6 | Pages: 972-976

10.2337/diacare.21.6.972 | PMID 9614616 Get It

OBJECTIVE To compare the compliance with diabetes care performance indicators by diabetes specialists using a diabetes electronic management system (DEMS) and by those using the traditional paper medical record. RESEARCH DESIGN AND METHODS A DEMS has been gradually introduced into our subspecialty practice for diabetes care. To assess the value of this DEMS as a disease management tool, we completed a retrospective review of the medical records of 82 randomly selected patients attending a subspecialty diabetes clinic (DC) during the first quarter of 1996. Eligible patients were defined by the suggested criteria from the American Diabetes Association Provider Recognition Program. During the first quarter of 1996, ∼ one half of the providers began using the DEMS for some but not all of their patient encounters. Neither abstractors nor providers were aware of the intent to examine performance in relationship to use of the DEMS. RESULTS Several measures were positively influenced when providers used the DEMS. The number of foot examinations, the number of blood pressure readings, and a weighted criterion score were greater (P < 0.01) for providers using the DEMS. There was evidence, although not statistically significant, for lower mean diastolic blood pressures (P = 0.043) in patients and for number of glycated hemoglobins documented (P = 0.018) by users of the DEMS. CONCLUSIONS Performance and documentation of the process of care for patients with diabetes in a subspecialty clinic are greater with the use of a DEMS than with the traditional paper record.
Radical pancreatoduodenectomy for misdiagnosed pancreatic mass
Smith, C. Daniel , Behrns, K.E. , Heerden, Jonathan A. van, Sarr, M. G.

Mayo Clinic

Journal of British Surgery | March 3, 2007 | Volume: 81 | Issue: 4 | Pages: 585-589

10.1002/bjs.1800810435 | PMID 7911387 Get It

Abstract Occasionally pancreatoduodenectomy is performed for clinically suspected pancreatic malignancy only for the surgeon to find that a benign aetiology accounts for the pancreatic mass. The aim of this study was twofold: to determine the incidence of pancreatoduodenectomy performed for a misdiagnosis of pancreatoduodenal malignancy and to identify potentially avoidable errors in preoperative and intraoperative judgement. Between 1956 and 1990, radical pancreatoduodenectomy was performed in 603 patients at the Mayo Clinic; 29 (5 per cent) underwent pancreatoduodenectomy for a diagnosis made before and during surgery of primary pancreatic or periampullary malignancy that was later proven histopathologically to be either unsuspected subacute or chronic pancreatitis (22 patients), benign fibrous common bile duct stricture (two), and penetrating duodenal ulcer, metastatic melanoma, ampullary adenoma, intrahepatic drug-induced cholestasis and pseudocyst (one each). No patient had a preoperative diagnosis of chronic pancreatitis. Weight loss, pain and/or jaundice were present in 27 of the 29 patients. Objective imaging tests, such as computed tomography, ultrasonography and/or endoscopic retrograde cholangio-pancreatography, were performed in 25 patients. Potential errors in judgement may be avoided by a more aggressive attempt at biopsy in selected patients; in others, resection for presumed malignancy may be unavoidable.
Deficiency of co-chaperone immunophilin FKBP52 compromises sperm fertilizing capacity
Hong, Ji-Young, Kim, Sung Tae , Tranguch, Susanne , Smith, David F. , Dey, Sudhansu K.

Mayo Clinic

Reproduction | February 16, 2007 | Volume: 133 | Issue: 2 | Pages: 395-403

10.1530/rep-06-0180 | PMID 17307907 Get It

Abstract FKBP52 is a member of the FK506-binding family of immunophilins and serves as a co-chaperone for steroid hormone nuclear receptors to govern appropriate hormone action in target tissues. Male mice missing Fkbp52 are infertile, and this infertility has been ascribed to compromised sensitivity of the anterior prostate, external genitalia, and other accessory sex organs to androgen. Here, we show additional defects contributing to infertility. We found that epididymal Fkbp52−/− sperm are sparse often with aberrant morphology, and they have reduced fertilizing capacity. This phenotype, initially observed in null males on a C57BL/6/129 background, is also maintained on a CD1 background. Expression studies show that while FKBP52 and androgen receptor are co-expressed in similar cell types in the epididymis, FKBP52 is also present in epididymal sperm flagella. Collectively, our results suggest that reduced number and abnormal morphology contribute to compromised fertilizing capacity of Fkbp52−/− sperm. This study is clinically relevant because unraveling the role of immunophilin signaling in male fertility will help identify new targets for male contraceptives and/or alleviate male infertility.
Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey–Osterrieth Complex Figure
Ivnik, Robert J., Smith, Glenn E. , Ferman, Tanis J. , Petersen, Ronald C. , Tangalos, Eric G., Machulda, Mary M. , Boeve, Bradley F. , Knopman, David S. , Ferman, Tanis J

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | December 21, 2006 | Volume: 29 | Issue: 4 | Pages: 377-384

10.1080/13803390600726803 | PMID 17497561 Get It

Innovative Reflecting Interview: Effect on High-Utilizing Patients with Medically Unexplained Symptoms
Rasmussen, Norman H., Furst, Joseph W. , Swenson-Dravis, Dana M., Agerter, David C., Smith, Alan J., Baird, Macaran A., Cha, Stephen S., Cha, Stephen S.

Mayo Clinic

Disease Management | November 20, 2006 | Volume: 9 | Issue: 6 | Pages: 349-359

10.1089/dis.2006.9.349 | PMID 17115882 Get It

Preliminary Results of Sacral Neuromodulation in 23 Children
Humphreys, Mitchell R. , Vandersteen, David R. , Slezak, Jeffery M., Hollatz, Pam, Smith, Craig A., Smith, Janet E. , Reinberg, Yuri

Mayo Clinic

Journal of Urology | October 26, 2006 | Volume: 176 | Issue: 5 | Pages: 2227-2231

10.1016/j.juro.2006.07.013 | PMID 17070300 Get It

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Geyer, Susan M. , Call, Timothy G. , Jelinek, Diane F., Tschumper, Renee C. , Bone, Nancy D., Dewald, Gordon W., Lin, Thomas S., Heerema, Nyla A. , Smith, Lisa , Grever, Michael R., Byrd, John C., Byrd, John C. , Kay, Neil E. , Shanafelt, Tait D. , Zent, Clive S. , Byrd, John C

Mayo Clinic

Blood | September 29, 2006 | Volume: 109 | Issue: 2 | Pages: 405-411

10.1182/blood-2006-07-033274 | PMID 17008537 Get It

AbstractBuilding on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and rituximab (375 mg/m2) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were high Rai risk, 71% were nonmutated for the immunoglobulin heavy-chain variable region gene, 34% were CD38+, and 34% were ZAP-70+. Thirty patients (52%) had one anomaly detected by fluorescence in situ (FISH) hybridization, and 21 (36%) had complex FISH defects. Thirty-eight patients (58%) had grade 3+ hematologic toxicity but minimal transfusion needs and no major infections. Responses occurred in 58 patients (91%), with 26 (41%) complete responses (CRs), 14 (22%) nodular partial responses (nodular PRs), and 18 (28%) partial responses (PRs). Many patients with a CR also lacked evidence of minimal residual disease by 2-color flow cytometry. Examination of prognostic factors demonstrated poor response in the 3 patients with del(17p). In contrast, we found this regimen was equally effective in young versus older (> 70 years) patients and in del(11q22.3) versus other favorable prognostic factors. Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previously untreated patients with CLL demonstrated significant clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in some, and modest toxicity.